Ozempic copies restricted after US judge denies injunction – One America News Network

0
131

By Patrick Wingrove and Dan Levine

April 25, 2025 – 6:29 AM PDT

Advertisement

REUTERS/Hollie Adams

(Reuters) – A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk’s (NOVOb.CO) popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug shortages unfolds, court records showed.

The decision came in response to a February lawsuit from a compounding industry group against the U.S. Food and Drug Administration’s decision that there was no longer a shortage of the medicines’ active ingredient, semaglutide.

Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand.

They had been allowed to produce hundreds of thousands of doses of copies of Novo’s obesity and diabetes drugs only while the FDA said…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here